In MDA-MB-231 breast cancer cells, TLR4 silencing reduced cell proliferation and secretion of the proinflammatory cytokines IL8 and IL6, which are known to contribute to immune evasion and resistance to immunotherapy [55,56]. This evidence concerns the gene TLR4 and breast carcinoma.